Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

SELL
$0.14 - $695.9 $2,926 - $14.5 Million
-20,900 Reduced 42.67%
28,084 $3,000
Q3 2022

Nov 09, 2022

BUY
$0.5 - $523.8 $44 - $46,618
89 Added 0.18%
48,984 $25,000
Q2 2022

Aug 11, 2022

BUY
$0.63 - $2.58 $20,089 - $82,271
31,888 Added 187.5%
48,895 $43,000
Q1 2022

May 12, 2022

SELL
$1.65 - $3.12 $19,780 - $37,402
-11,988 Reduced 41.35%
17,007 $43,000
Q4 2021

Feb 11, 2022

SELL
$2.31 - $5.85 $89,020 - $225,441
-38,537 Reduced 57.06%
28,995 $75,000
Q3 2021

Nov 12, 2021

BUY
$4.55 - $10.36 $307,270 - $699,631
67,532 New
67,532 $309,000
Q4 2020

Feb 10, 2021

SELL
$7.81 - $10.39 $139,947 - $186,178
-17,919 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$6.34 - $10.83 $268,023 - $457,838
-42,275 Reduced 70.23%
17,919 $183,000
Q2 2020

Aug 13, 2020

BUY
$4.6 - $8.6 $152,315 - $284,763
33,112 Added 122.27%
60,194 $403,000
Q1 2020

May 13, 2020

SELL
$3.51 - $6.17 $351 - $617
-100 Reduced 0.37%
27,082 $123,000
Q4 2019

Feb 10, 2020

BUY
$5.76 - $7.35 $150,232 - $191,702
26,082 Added 2371.09%
27,182 $165,000
Q3 2019

Nov 12, 2019

BUY
$6.46 - $8.37 $7,106 - $9,207
1,100 New
1,100 $8,000
Q2 2019

Aug 09, 2019

SELL
$6.34 - $8.8 $2,415 - $3,352
-381 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$6.06 - $9.0 $5,454 - $8,100
-900 Reduced 70.26%
381 $3,000
Q4 2018

Feb 06, 2019

SELL
$5.18 - $9.35 $802 - $1,449
-155 Reduced 10.79%
1,281 $7,000
Q3 2018

Nov 08, 2018

BUY
$6.0 - $11.35 $8,616 - $16,298
1,436 New
1,436 $13,000

Others Institutions Holding RDHL

About RedHill Biopharma Ltd.


  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $364M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.